You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

233 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Oct 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
Exceptional Access Program
    fruquintinib - For the treatment of metastatic colorectal cancer according to specific criteria
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Mar 2026
Drug
Other Name(s): Zolinza®
Updated
Mar 2026
Guidelines and Advice
Guidelines and Advice

Pages